NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|4505029|ref|NP_000886|]
View 

leukotriene A-4 hydrolase isoform 1 [Homo sapiens]

Protein Classification

M1 family metallopeptidase( domain architecture ID 11494248)

M1 family metallopeptidase such as aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
6-608 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


:

Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1049.75  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029      6 DTCSLASPAsVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGS 85
Cdd:TIGR02411   1 DPSSLSNYK-DFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029     86 PMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPk 165
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP- 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    166 eLVALMSAIRDGETPdpEDPSRKIYKfiQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFS-ETESMLKI 244
Cdd:TIGR02411 159 -LPVLMSGIRDGETS--NDPGKYLFK--QKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKT 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    245 AEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVY 324
Cdd:TIGR02411 234 AEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVY 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    325 LERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIF 404
Cdd:TIGR02411 314 LERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    405 LGFLKAYVEKFSYKSITTDDWKDFLYSYFKD--KVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKE- 481
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKa 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    482 DDLNSFNATDLKDLSSHQLNEFLAQTLQR---APLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKM 558
Cdd:TIGR02411 474 DDLSSFNAKDIKDFSSHQLVLFLETLTERggdWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 4505029    559 ATEQGRMKFTRPLFKDLAAFdKSHDQAVRTYQEHKASMHPVTAMLVGKDL 608
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
6-608 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1049.75  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029      6 DTCSLASPAsVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGS 85
Cdd:TIGR02411   1 DPSSLSNYK-DFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029     86 PMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPk 165
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP- 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    166 eLVALMSAIRDGETPdpEDPSRKIYKfiQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFS-ETESMLKI 244
Cdd:TIGR02411 159 -LPVLMSGIRDGETS--NDPGKYLFK--QKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKT 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    245 AEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVY 324
Cdd:TIGR02411 234 AEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVY 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    325 LERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIF 404
Cdd:TIGR02411 314 LERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    405 LGFLKAYVEKFSYKSITTDDWKDFLYSYFKD--KVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKE- 481
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKa 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    482 DDLNSFNATDLKDLSSHQLNEFLAQTLQR---APLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKM 558
Cdd:TIGR02411 474 DDLSSFNAKDIKDFSSHQLVLFLETLTERggdWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 4505029    559 ATEQGRMKFTRPLFKDLAAFdKSHDQAVRTYQEHKASMHPVTAMLVGKDL 608
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
6-450 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 789.73  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    6 DTCSLASPASVcRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVING-QEVKYALGERQSYKG 84
Cdd:cd09599   1 DPSSFSNYDEV-RTTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLG 79
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   85 SPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVP 164
Cdd:cd09599  80 SALTITLPSPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVP 159
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  165 KELVALMSAIRDGEtpdPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKI 244
Cdd:cd09599 160 KGLTALMSALRTGE---KEEAGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKA 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  245 AEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVY 324
Cdd:cd09599 237 AEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVY 316
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  325 LERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQlLGGPEIF 404
Cdd:cd09599 317 LERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQ-LGGREVF 395
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*..
gi 4505029  405 LGFLKAYVEKFSYKSITTDDWKDFLYSYF-KDKVDVLNQVDWNAWLY 450
Cdd:cd09599 396 DPFLRAYFKKFAFQSIDTEDFKDFLLEYFaEDKPEILDKIDWDAWLY 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
18-589 3.94e-113

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 350.87  E-value: 3.94e-113
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   18 RTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYalgerqSYKGSPMEISLPIALSK 97
Cdd:COG0308  16 DVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLDF------TRDGERLTITLPKPLAP 89
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   98 NQEIVIEISFETSPKSS--ALQWLTPEqtsGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIR 175
Cdd:COG0308  90 GETFTLEIEYSGKPSNGgeGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSNGNL 166
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  176 DGETPDPEDpsRKIYKFIQKVPIPCYLIALVVGALESRQI----GPRTLVWSEKEQVEKSAYEFSETESMLKIAEDL-GG 250
Cdd:COG0308 167 VSETELGDG--RTTWHWADTQPIPTYLFALAAGDYAVVEDtfasGVPLRVYVRPGLADKAKEAFESTKRMLDFFEELfGV 244
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  251 PYVWGQYDLLVLPpSFPYGGMENPCLTFVTPTLLAGD-------KSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTV 323
Cdd:COG0308 245 PYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADEtatdadyERRESVIAHELAHQWFGNLVTCADWDDLWLNEGFAT 323
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  324 YLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPftklVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLgGPEI 403
Cdd:COG0308 324 YMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHP----IRPDDYPEIENFFDGIVYEKGALVLHMLRTLL-GDEA 398
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  404 FLGFLKAYVEKFSYKSITTDDWKDFLYsyfkdkvDVLNQ-VDW--NAWLYSPGLPPIKPNYDMTlTNACIALSQRWITAK 480
Cdd:COG0308 399 FRAGLRLYFARHAGGNATTEDFLAALE-------EASGRdLSAffDQWLYQAGLPTLEVEYEYD-ADGKVTLTLRQTPPR 470
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  481 EDDLN---SFNATDLKDLSSHQLNEFLAQTLQRAPLPLgHIKRMQEVYNFNAINNSEIRFRWlrLCIQSKWEDAIPLALK 557
Cdd:COG0308 471 PHPFHiplEVGLLGGKLTARTVLLDGEQTELVAKPDPV-LLLRLDDELAFLLAHDSDPFNRW--EALQALWRDGEADYLD 547
                       570       580       590
                ....*....|....*....|....*....|..
gi 4505029  558 mATEQGRMKFTRPLFKDLAAFDKSHDQAVRTY 589
Cdd:COG0308 548 -ALRALADTDPAVRAEALALLGSDQLALARAA 578
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
233-444 5.80e-58

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 193.66  E-value: 5.80e-58
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    233 YEFSETESMLKIAED-LGGPYVWGQYDLLVLPpSFPYGGMENPCLTFVTPTLLAGD---------KSLSNVIAHEISHSW 302
Cdd:pfam01433   1 YALEITVKLLEFYEDyFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    303 TGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEkfRHFNALGGWGELQN--SVKTFGETHPFTKLVVDLTDIDPdvAYS 380
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDALFPE--WNIWEQFLLDEVQNamARDALDSSHPITQNVNDPSEIDD--IFD 155
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 4505029    381 SVPYEKGFALLFYLEQLLgGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSyFKDKVDVLNQVD 444
Cdd:pfam01433 156 AIPYEKGASVLRMLETLL-GEEVFQKGLRSYLKKFQYGNATTEDLWDALSE-ASGPLDVDSFMD 217
pepN PRK14015
aminopeptidase N; Provisional
38-324 2.82e-09

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 60.14  E-value: 2.82e-09
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    38 TAALTV--QSQEDNLRSLVLDTKDLTIEKVVINGQEVK---YALGERQsykgspMEISLPialskNQEIVIEISFETSPK 112
Cdd:PRK14015  38 TARLQVrrNPDAAHSAPLVLDGEDLELLSLALDGQPLApsaYELDEEG------LTIENL-----PDRFTLEIETEIDPE 106
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   113 S-SALQWLTpeQTSGKehpyLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKEL--VaLMS---AIRDGETPDP---- 182
Cdd:PRK14015 107 AnTALEGLY--RSGGM----FCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKypV-LLSngnLVESGELPDGrhwa 179
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   183 --EDPSRKiykfiqkvpiPCYLIALVVGALES----------RQIgprTL-VWSEKEQVEKSAYefseteSM--LKIA-- 245
Cdd:PRK14015 180 twEDPFPK----------PSYLFALVAGDLDVledtfttrsgREV---ALeIYVEPGNLDKCDH------AMdsLKKSmk 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   246 --EDlggpyVWG-QYDL----LVLPPSFPYGGMENPCLT-FVTPTLLAG-----DKSLSN---VIAHEISHSWTGNLVTN 309
Cdd:PRK14015 241 wdEE-----RFGlEYDLdifmIVAVDDFNMGAMENKGLNiFNSKYVLADpetatDADYERiesVIAHEYFHNWTGNRVTC 315
                        330
                 ....*....|....*..
gi 4505029   310 KTWdhFWLN--EGHTVY 324
Cdd:PRK14015 316 RDW--FQLSlkEGLTVF 330
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
6-608 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1049.75  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029      6 DTCSLASPAsVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGS 85
Cdd:TIGR02411   1 DPSSLSNYK-DFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGS 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029     86 PMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPk 165
Cdd:TIGR02411  80 PLTISLPIATSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP- 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    166 eLVALMSAIRDGETPdpEDPSRKIYKfiQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFS-ETESMLKI 244
Cdd:TIGR02411 159 -LPVLMSGIRDGETS--NDPGKYLFK--QKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKT 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    245 AEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVY 324
Cdd:TIGR02411 234 AEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVY 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    325 LERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIF 404
Cdd:TIGR02411 314 LERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    405 LGFLKAYVEKFSYKSITTDDWKDFLYSYFKD--KVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKE- 481
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKa 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    482 DDLNSFNATDLKDLSSHQLNEFLAQTLQR---APLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKM 558
Cdd:TIGR02411 474 DDLSSFNAKDIKDFSSHQLVLFLETLTERggdWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 4505029    559 ATEQGRMKFTRPLFKDLAAFdKSHDQAVRTYQEHKASMHPVTAMLVGKDL 608
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
6-450 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 789.73  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    6 DTCSLASPASVcRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVING-QEVKYALGERQSYKG 84
Cdd:cd09599   1 DPSSFSNYDEV-RTTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLG 79
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   85 SPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVP 164
Cdd:cd09599  80 SALTITLPSPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVP 159
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  165 KELVALMSAIRDGEtpdPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKI 244
Cdd:cd09599 160 KGLTALMSALRTGE---KEEAGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKA 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  245 AEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVY 324
Cdd:cd09599 237 AEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVY 316
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  325 LERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQlLGGPEIF 404
Cdd:cd09599 317 LERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQ-LGGREVF 395
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*..
gi 4505029  405 LGFLKAYVEKFSYKSITTDDWKDFLYSYF-KDKVDVLNQVDWNAWLY 450
Cdd:cd09599 396 DPFLRAYFKKFAFQSIDTEDFKDFLLEYFaEDKPEILDKIDWDAWLY 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
20-431 1.01e-169

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 489.26  E-value: 1.01e-169
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   20 KHLHLRCSVDFTRRTLTGTAALTVQSQEdNLRSLVLDTKDLTIEKVVINGQEVKYalGERQSYKGSPMEISLPIAlsKNQ 99
Cdd:cd09595   1 YHYDLDLDVDFTTKTLNGTETLTVDASQ-VGRELVLDLVGLTIHSVSVNGAAVDF--GEREHYDGEKLTIPGPKP--PGQ 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  100 EIVIEISFETSPKSSALQWLTpEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGET 179
Cdd:cd09595  76 TFTVRISFEAKPSKNLLGWLW-EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKDLLASNGALVGEE 154
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  180 PDPEDpsRKIYKFIQKVPIPCYLIALVVGALESRQIGPRT------LVWSEKEQVEKSAYEFSETESMLKIAED-LGGPY 252
Cdd:cd09595 155 TGANG--RKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSqprvglSVYSEPLQVDQAQYAFDATRAALAWFEDyFGGPY 232
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  253 VWGQYDLLVLPPsFPYGGMENPCLTFVTPTLLA-------GDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYL 325
Cdd:cd09595 233 PLPKYDLLAVPD-FNSGAMENPGLITFRTTYLLrskvtdtGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYY 311
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  326 ERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVvdlTDIDPDVAYSSVPYEKGFALLFYLEQLLgGPEIFL 405
Cdd:cd09595 312 ENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTSTPVR---SPADPDVAYDGVTYAKGALVLRMLEELV-GEEAFD 387
                       410       420
                ....*....|....*....|....*.
gi 4505029  406 GFLKAYVEKFSYKSITTDDWKDFLYS 431
Cdd:cd09595 388 KGVQAYFNRHKFKNATTDDFIDALEE 413
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
18-589 3.94e-113

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 350.87  E-value: 3.94e-113
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   18 RTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYalgerqSYKGSPMEISLPIALSK 97
Cdd:COG0308  16 DVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLDF------TRDGERLTITLPKPLAP 89
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   98 NQEIVIEISFETSPKSS--ALQWLTPEqtsGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIR 175
Cdd:COG0308  90 GETFTLEIEYSGKPSNGgeGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSNGNL 166
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  176 DGETPDPEDpsRKIYKFIQKVPIPCYLIALVVGALESRQI----GPRTLVWSEKEQVEKSAYEFSETESMLKIAEDL-GG 250
Cdd:COG0308 167 VSETELGDG--RTTWHWADTQPIPTYLFALAAGDYAVVEDtfasGVPLRVYVRPGLADKAKEAFESTKRMLDFFEELfGV 244
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  251 PYVWGQYDLLVLPpSFPYGGMENPCLTFVTPTLLAGD-------KSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTV 323
Cdd:COG0308 245 PYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADEtatdadyERRESVIAHELAHQWFGNLVTCADWDDLWLNEGFAT 323
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  324 YLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPftklVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLgGPEI 403
Cdd:COG0308 324 YMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHP----IRPDDYPEIENFFDGIVYEKGALVLHMLRTLL-GDEA 398
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  404 FLGFLKAYVEKFSYKSITTDDWKDFLYsyfkdkvDVLNQ-VDW--NAWLYSPGLPPIKPNYDMTlTNACIALSQRWITAK 480
Cdd:COG0308 399 FRAGLRLYFARHAGGNATTEDFLAALE-------EASGRdLSAffDQWLYQAGLPTLEVEYEYD-ADGKVTLTLRQTPPR 470
                       490       500       510       520       530       540       550       560
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  481 EDDLN---SFNATDLKDLSSHQLNEFLAQTLQRAPLPLgHIKRMQEVYNFNAINNSEIRFRWlrLCIQSKWEDAIPLALK 557
Cdd:COG0308 471 PHPFHiplEVGLLGGKLTARTVLLDGEQTELVAKPDPV-LLLRLDDELAFLLAHDSDPFNRW--EALQALWRDGEADYLD 547
                       570       580       590
                ....*....|....*....|....*....|..
gi 4505029  558 mATEQGRMKFTRPLFKDLAAFDKSHDQAVRTY 589
Cdd:COG0308 548 -ALRALADTDPAVRAEALALLGSDQLALARAA 578
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
20-450 1.61e-70

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 233.63  E-value: 1.61e-70
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   20 KHLHLRCSVDFTRRTLTGTAALTVQSQEDnLRSLVLDTKDLTIEKVVINGQEVKYAlgerqSYKGSPMEISLPIALSKNQ 99
Cdd:cd09603   4 LHYDLDLDYDPATKSLSGTATITFRATQD-LDSLQLDLVGLTVSSVTVDGVPAAFF-----THDGDKLVITLPRPLAAGE 77
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  100 EIVIEISFETSPKSSALQWLTPEQTSGKeHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGET 179
Cdd:cd09603  78 TFTVTVRYSGKPRPAGYPPGDGGGWEEG-DDGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVVSNGRLVSTT 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  180 PDPEDpsRKIYKFIQKVPIPCYLIALVVGALES-RQIGPRTL---VWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWG 255
Cdd:cd09603 157 TNGGG--TTTWHWKMDYPIATYLVTLAVGRYAVvEDGSGGGIplrYYVPPGDAAKAKASFARTPEMLDFFEELFGPYPFE 234
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  256 QYDLLVLPPSfpYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLErhicgRLFG 335
Cdd:cd09603 235 KYGQVVVPDL--GGGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAE-----WLWS 307
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  336 EkfRHFNALGGWGELQNSVKTFGETHPftklvVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLgGPEIFLGFLKAYVEKF 415
Cdd:cd09603 308 E--HKGGADAYRAYLAGQRQDYLNADP-----GPGRPPDPDDLFDRDVYQKGALVLHMLRNLL-GDEAFFAALRAYLARY 379
                       410       420       430       440
                ....*....|....*....|....*....|....*....|..
gi 4505029  416 SYKSITTDDWKDFL-------YSYFkdkvdvlnqvdWNAWLY 450
Cdd:cd09603 380 AHGNVTTEDFIAAAeevsgrdLTWF-----------FDQWLY 410
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
233-444 5.80e-58

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 193.66  E-value: 5.80e-58
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    233 YEFSETESMLKIAED-LGGPYVWGQYDLLVLPpSFPYGGMENPCLTFVTPTLLAGD---------KSLSNVIAHEISHSW 302
Cdd:pfam01433   1 YALEITVKLLEFYEDyFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    303 TGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEkfRHFNALGGWGELQN--SVKTFGETHPFTKLVVDLTDIDPdvAYS 380
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDALFPE--WNIWEQFLLDEVQNamARDALDSSHPITQNVNDPSEIDD--IFD 155
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 4505029    381 SVPYEKGFALLFYLEQLLgGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSyFKDKVDVLNQVD 444
Cdd:pfam01433 156 AIPYEKGASVLRMLETLL-GEEVFQKGLRSYLKKFQYGNATTEDLWDALSE-ASGPLDVDSFMD 217
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
21-444 8.88e-56

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 195.11  E-value: 8.88e-56
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   21 HLHLRCSVDFTRRTLTGTAALTVQSQEDNlRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSP--MEISLPIALSKN 98
Cdd:cd09601   2 HYDLTLTPDLENFTFSGSVTITLEVLEPT-DTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETefLTITLDETLPPG 80
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   99 QEIVIEISF--ETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVAL--MSAI 174
Cdd:cd09601  81 ENYTLSIEFtgKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALsnMPPV 160
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  175 RDGETPDpedpSRKIYKFIQKVPIPCYLIALVVGALESRQI----GPRTLVWSEKEQVEKSAYEFSETESMLKIAED-LG 249
Cdd:cd09601 161 ESTELED----GWKTTTFETTPPMSTYLVAFVVGDFEYIESttksGVPVRVYARPGKIEQGDFALEVAPKILDFYEDyFG 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  250 GPYVWGQYDLLVLPpSFPYGGMENP-CLTFVTPTLLAGDKSLS--------NVIAHEISHSWTGNLVTNKTWDHFWLNEG 320
Cdd:cd09601 237 IPYPLPKLDLVAIP-DFAAGAMENWgLITYRETALLYDPKTSSasdkqrvaEVIAHELAHQWFGNLVTMKWWDDLWLNEG 315
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  321 HTVYLERHICGRLFGE--KFRHFNAlggwGELQN-----SVKTfgeTHPFTKLVVDLTDIDPdvAYSSVPYEKGFALLFY 393
Cdd:cd09601 316 FATYMEYLAVDKLFPEwnMWDQFVV----DELQSaleldSLAS---SHPIEVPVESPSEISE--IFDAISYSKGASVLRM 386
                       410       420       430       440       450
                ....*....|....*....|....*....|....*....|....*....|.
gi 4505029  394 LEQLLgGPEIFLGFLKAYVEKFSYKSITTDDwkdfLYSYFKDKVDVLNQVD 444
Cdd:cd09601 387 LENFL-GEEVFRKGLRKYLKKHAYGNATTDD----LWEALQEASGESKPLD 432
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
495-608 4.40e-49

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 166.13  E-value: 4.40e-49
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    495 LSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKD 574
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVYKLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYRA 80
                          90       100       110
                  ....*....|....*....|....*....|....
gi 4505029    575 LAAFDKshDQAVRTYQEHKASMHPVTAMLVGKDL 608
Cdd:pfam09127  81 LNKVDR--DLAVETFEKNKDFYHPICRAMVEKDL 112
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
21-448 5.88e-47

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 171.16  E-value: 5.88e-47
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   21 HLHLrcsvDFTR--RTLTGTAALTVQSQEDNlRSLVLDTKDLTIEKVVINGQEVKYAL--GERqsykgspmeISLPiALS 96
Cdd:cd09602  19 DLDL----DLTEgaETFRGTVTIRFTLREPG-ASLFLDFRGGEVKSVTLNGRPLDPSAfdGER---------ITLP-GLL 83
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   97 KNQEIVIEISFETspkssalqwltPEQTSGK-EH---------PYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKE 166
Cdd:cd09602  84 KAGENTVVVEFTA-----------PYSSDGEgLHrfvdpadgeTYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPAD 152
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  167 LVALMSAirdGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALES--RQIGPRTLVW----SEKEQVEKSAYEFSETES 240
Cdd:cd09602 153 WTVISNG---PETSTEEAGGRKRWRFAETPPLSTYLFAFVAGPYHRveDEHDGIPLGLycreSLAEYERDADEIFEVTKQ 229
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  241 MLKIAEDLGG-PYVWGQYDLlVLPPSFPYGGMENP-CLTF---------VTPTLLAGdksLSNVIAHEISHSWTGNLVTN 309
Cdd:cd09602 230 GLDFYEDYFGiPYPFGKYDQ-VFVPEFNFGAMENPgAVTFresylfreePTRAQRLR---RANTILHEMAHMWFGDLVTM 305
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  310 KTWDHFWLNEGHTVYLERHICGRLFGEK--FRHFNALGGWGEL-QNSVKTfgeTHPftkLVVDLTDIdpDVA---YSSVP 383
Cdd:cd09602 306 KWWDDLWLNESFADFMAAKALAEATPFTdaWLTFLLRRKPWAYrADQLPT---THP---IAQDVPDL--EAAgsnFDGIT 377
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 4505029  384 YEKGFALLFYLEQLLgGPEIFLGFLKAYVEKFSYKSITtddWKDFLysyfkdkvDVLNQV---DWNAW 448
Cdd:cd09602 378 YAKGASVLKQLVALV-GEEAFRAGLREYFKKHAYGNAT---LDDLI--------AALDEAsgrDLSAW 433
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
235-329 1.81e-29

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 112.19  E-value: 1.81e-29
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  235 FSETESMLKIAEDLGG-----PYVWGQYDLLVLPP---SFPYGGMENP-CLTFVTPTLLAGDKSLSNVIAHEISHSWTGN 305
Cdd:cd09594   1 TSYAHETYKYYEELLGrtsfrYPVSPIYSLLVYPAyveVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQ 80
                        90       100
                ....*....|....*....|....*
gi 4505029  306 LVTNK-TWDHFWLNEGHTVYLERHI 329
Cdd:cd09594  81 FSNLMySWSSGWLNEGISDYFGGLV 105
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
23-449 2.17e-28

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 118.15  E-value: 2.17e-28
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   23 HLRCSVDFTRRTLTGTAALTVQSQE-DNLRSLVL--------------------------DTKDLTIEKVVINGQEVKYa 75
Cdd:cd09604   2 DIDVTLDPETHTLTGKETITYTNNSpDTLDELYFhlypnafkpgstmpardsriaklkgdEPGGIDIDSVKVNGKGLKL- 80
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   76 lgeRQSYKGSPMEISLPIALSKNQEIVIEISFETS-PKSSAlqwltpeQTSGKEHPYLFSQCQAI---------HCRAIL 145
Cdd:cd09604  81 ---EVTLTITRLKLALPLPLKPGESVTVEIDFTVKlPEQGG-------RFGYDGDEYNLAQWYPKlavyddggwNTDPYY 150
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  146 PCQDTP-SVKLTYTAEVSVPKELVALMSAIRDgeTPDPEDPSRKIYKFIQK-------VPIPCYLIalvvgaLESRQIGP 217
Cdd:cd09604 151 GRGEFFySDFGDYDVTITVPKNYVVAATGELQ--NPEEVLDGTKTWHFKAEnvrdfawAASPDFVV------DAATVDGV 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  218 RTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLlVLPPSFpYGGMENPCLTFVTPTLLAGDKSLSNVIAHE 297
Cdd:cd09604 223 TVNVYYLPENAEAAERALEYAKDALEFFSEKFGPYPYPELDV-VQGPFG-GGGMEYPGLVFIGSRLYDPKRSLEGVVVHE 300
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  298 ISHSWTGNLVTNKTWDHFWLNEGHTVYLErhicgRLFGEKFrhFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDV 377
Cdd:cd09604 301 IAHQWFYGIVGNDERREPWLDEGLATYAE-----SLYLEEK--YGKEAADELLGRRYYRAYARGPGGPINLPLDTFPDGS 373
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 4505029  378 AYSSVPYEKGFALLFYLEQLLgGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLnqvdWNAWL 449
Cdd:cd09604 374 YYSNAVYSKGALFLEELREEL-GDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSGKDLDWF----FRGWL 440
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
21-202 8.40e-26

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 104.73  E-value: 8.40e-26
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029     21 HLHLRCSVDFTRRTLTGTAALTVQSQEdNLRSLVLDTKDLTIEKVVINGQ---EVKYALGERQSYKGSPMEISLPIALSK 97
Cdd:pfam17900   4 HYDLDLKIDLKNFTFSGSVTITLQLNN-ATNVIVLHASDLTIRSISLSDEvtsDGVPADFTEDQKDGEKLTIVLPETLNQ 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029     98 NQEIVIEISFET--SPKSSALQWLTpEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALmSAIR 175
Cdd:pfam17900  83 TGPYTLEIEYSGelNDSMTGFYRST-YTDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTAL-SNMP 160
                         170       180
                  ....*....|....*....|....*..
gi 4505029    176 DGETpDPEDPSRKIYKFIQKVPIPCYL 202
Cdd:pfam17900 161 VIAS-EPLENGWVITTFEQTPKMSTYL 186
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
20-425 3.06e-23

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 102.59  E-value: 3.06e-23
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   20 KHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVK---YALGERQsykgspmeisLPIaLS 96
Cdd:cd09600  10 DHVDLDFDLDDDETIVTSRLRVRRNPDSGEGAPLVLDGEDLELLSVKIDGKPLSpsdYTLDEEG----------LTI-KN 78
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   97 KNQEIVIEISFETSPKS-SALQWLtpeQTSGKehpYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSA-- 173
Cdd:cd09600  79 VPDRFVLEIEVRINPAAnTSLEGL---YKSGG---ILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVLLSng 152
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  174 --IRDGETPDP------EDPSRKiykfiqkvpiPCYLIALVVGALES----------RQIgprTL-VWSEKEQVEKSAYE 234
Cdd:cd09600 153 nlIEEGELPNGrhfavwEDPFPK----------PSYLFALVAGDLGSvedtfttksgRKV---KLrIYVEPGNEDKCHHA 219
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  235 FsetESmLKIA----EDlggpyVWG-QYDL----LVLPPSFPYGGMENPCLT-FVTPTLLAG-----DKSLSN---VIAH 296
Cdd:cd09600 220 M---ES-LKKAmkwdEE-----RFGlEYDLdlfnIVAVDDFNMGAMENKGLNiFNSKYVLADpetatDADYERiesVIAH 290
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  297 EISHSWTGNLVTNKTWDHFWLNEGHTVYLErhicgRLFGEKfrhfnalggwgelQNS--------VKT-----FGE---- 359
Cdd:cd09600 291 EYFHNWTGNRVTCRDWFQLSLKEGLTVFRD-----QEFSAD-------------MNSravkriedVRRlrsaqFPEdagp 352
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 4505029  360 -THPftklvvdltdIDPDvAYSSVP-------YEKGFALLFYLEQLLgGPEIFLGFLKAYVEKFSYKSITTDDW 425
Cdd:cd09600 353 mAHP----------IRPD-SYIEINnfytvtvYEKGAEVIRMLHTLL-GEEGFRKGMDLYFERHDGQAVTCEDF 414
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
28-339 4.32e-17

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 84.59  E-value: 4.32e-17
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   28 VDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKY------------------ALGERQSYKGSP--- 86
Cdd:cd09839  10 VDFANRSIIGYTEITIVPTSPDLRTIRLNCRQCKIKSVTVNGVEAEFtyndplqnldlsdntdvnAHHELKRKLAAAlae 89
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   87 -------MEISLP---------------IALSKNQE--------IVIEISFE-TSPKSsALQWLTPEQTSGKEHPYLFSQ 135
Cdd:cd09839  90 pdegneeLVISLPpsvkielqdpnsastQATTSSPDtsedeftpLTIRIEYSlKNPRD-GLHFVGPDEGGDKRYPHVYTT 168
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  136 CQAIHCRA--ILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETP-----------------------------DPED 184
Cdd:cd09839 169 NSPLPGSArcWFPCVDSLWERCTWELEITVPRTLGDAGRPPLAGSKEdeddddlteedkelemvvvcsgdlveqvvHPED 248
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  185 PSRKIYKFIQKVPIPCYLIALVVGALE----SRQIGPRTLVWSEKEQVEKSAYEFSETESMLK-----IA------EDLG 249
Cdd:cd09839 249 PSKKTFSFSLSNPTSAQHIGFAVGPFEivplPEFRESEEDDKLGSSAVEVTGFCLPGRLEELRntcsfLHkamdffEEEY 328
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029  250 GPYVWGQYDLLVLPP----SFPYGGmenpcLTFVTPTLLAGDKSL------SNVIAHEISHSWTGNLVTNKTWDHFWLne 319
Cdd:cd09839 329 GSYPFSSYKQVFVDDlpedVSSFAS-----LSICSSRLLYPPDIIdqayetRRKLAHALASQWFGINIIPKTWSDTWL-- 401
                       410       420
                ....*....|....*....|....*..
gi 4505029  320 ghTVYLERHICG----RLFGE---KFR 339
Cdd:cd09839 402 --VIGIAGYMTGlflkKLFGNneyRFR 426
pepN PRK14015
aminopeptidase N; Provisional
38-324 2.82e-09

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 60.14  E-value: 2.82e-09
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029    38 TAALTV--QSQEDNLRSLVLDTKDLTIEKVVINGQEVK---YALGERQsykgspMEISLPialskNQEIVIEISFETSPK 112
Cdd:PRK14015  38 TARLQVrrNPDAAHSAPLVLDGEDLELLSLALDGQPLApsaYELDEEG------LTIENL-----PDRFTLEIETEIDPE 106
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   113 S-SALQWLTpeQTSGKehpyLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKEL--VaLMS---AIRDGETPDP---- 182
Cdd:PRK14015 107 AnTALEGLY--RSGGM----FCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKypV-LLSngnLVESGELPDGrhwa 179
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   183 --EDPSRKiykfiqkvpiPCYLIALVVGALES----------RQIgprTL-VWSEKEQVEKSAYefseteSM--LKIA-- 245
Cdd:PRK14015 180 twEDPFPK----------PSYLFALVAGDLDVledtfttrsgREV---ALeIYVEPGNLDKCDH------AMdsLKKSmk 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 4505029   246 --EDlggpyVWG-QYDL----LVLPPSFPYGGMENPCLT-FVTPTLLAG-----DKSLSN---VIAHEISHSWTGNLVTN 309
Cdd:PRK14015 241 wdEE-----RFGlEYDLdifmIVAVDDFNMGAMENKGLNiFNSKYVLADpetatDADYERiesVIAHEYFHNWTGNRVTC 315
                        330
                 ....*....|....*..
gi 4505029   310 KTWdhFWLN--EGHTVY 324
Cdd:PRK14015 316 RDW--FQLSlkEGLTVF 330
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH